8-K: Tenax Therapeutics Appoints New CFO, Thomas R. Staab, II

Tenax Therapeutics announced the appointment of Thomas R. Staab, II as its new Chief Financial Officer, effective May 11, 2026, replacing interim CFO Thomas A. McGauley.

Summary

• Tenax Therapeutics, Inc. has appointed Thomas R. Staab, II as its new Chief Financial Officer (CFO), effective May 11, 2026.
• Mr. Staab brings over 25 years of financial and executive experience in the healthcare industry.
• He previously served as CFO for LENSAR, Inc. and held senior finance roles at BioCryst Pharmaceuticals, Inc., Inspire Pharmaceuticals, and Triangle Pharmaceuticals, Inc.
• Thomas A. McGauley, the current Interim CFO, will transition out of his role after filing the upcoming Quarterly Report on Form 10-Q for the quarter ended March 31, 2026.
• Mr. Staab will receive an annual base salary of $428,000, a target annual bonus of 45% of his base salary, and equity awards including 10,000 restricted stock units and options to purchase 450,000 shares of common stock.
• The company is developing levosimendan (TNX-103) for the treatment of PH-HFpEF, a condition with no currently approved therapies.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the addition of a highly experienced CFO, which is crucial for a company in its stage of development, though the company's success remains contingent on clinical and regulatory outcomes.

Positives

• Appointment of an experienced CFO, Thomas R. Staab, II, with over 25 years in healthcare finance leadership.
• Mr. Staab's extensive background includes CFO roles at LENSAR, Inc. and significant experience at BioCryst Pharmaceuticals, Inspire Pharmaceuticals, and Triangle Pharmaceuticals.
• The company is advancing a potentially first-in-class therapy (levosimendan for PH-HFpEF) with a significant unmet medical need.
• Inducement equity awards granted to the new CFO to align interests and incentivize performance.
• The interim CFO, Thomas A. McGauley, is recognized for his contributions during a period of expansion.

Negatives

• The company is still in the development stage (Phase 3) and has not yet brought a product to market.
• Reliance on third parties for manufacturing and clinical research operations.
• Significant cash needs are a stated risk.

Risks

• Risks associated with clinical trials, including timing, delays, costs, design, enrollment, and results.
• Potential delays in regulatory review and approval of product candidates.
• Risks related to the company's business strategy and prioritization of product candidates.
• Reliance on third parties, including manufacturers and CROs.
• Risks concerning the formulation, production, marketing, customer acceptance, and clinical utility of product candidates.
• Intellectual property risks.
• Volatility and uncertainty in the global economy and financial markets.
• Changes in legal, regulatory, and legislative environments impacting regulatory approval.

Future Outlook

The company is advancing its registrational program globally and building strategic capabilities for levosimendan, aiming to be the first therapy for PH-HFpEF patients. The new CFO will support the company's long-term success and advancement of TNX-103.

Management Comments

• "Tom brings decades of experience as a CFO, leading strategic finance functions, growing and integrating organizations, and launching products at multiple healthcare companies. He joins at a crucial moment in Tenax's evolution, as we expand our registrational program globally and begin building out strategic capabilities key to levosimendan's future as potentially the first available therapy for PH-HFpEF patients."
• "We are delighted to welcome Tom and look forward to leveraging his considerable knowledge of the biotech investment world, and his C-suite experience in biotech, as we advance TNX-103 over the coming years."
• "Our interim CFO, Tom McGauley, has done a phenomenal job modernizing and growing our finance organization during a vital period of expansion. The Board and I are grateful for his tireless focus on finance and operational execution, and the strategic guidance he has provided Tenax on so many levels."
• "I am excited to join Tenax and support an organization focused on developing a novel, potential first-in-class therapy for an indication with such a significant unmet need. I look forward to partnering with the leadership team and Board of Directors to position the company for long-term success."

Industry Context

StockSavvy.ai notes that the appointment of an experienced CFO is a critical step for a development-stage pharmaceutical company like Tenax Therapeutics, especially as it advances its lead candidate, levosimendan, into later-stage clinical trials and prepares for potential commercialization. The focus on PH-HFpEF, a condition with no current treatments, highlights the company's strategic positioning in a high-need area of cardiovascular medicine.

Management Changes

Stakeholder Impact

• Shareholders: The appointment of an experienced CFO may instill confidence in financial management and strategic execution, potentially impacting investor sentiment.
• Employees: The transition in financial leadership provides stability and clarity for the finance and accounting teams.
• Creditors/Lenders: A strong financial leadership team can positively influence perceptions of financial stability and operational oversight.

Next Steps

• Thomas R. Staab, II to assume CFO responsibilities effective May 11, 2026.
• Thomas A. McGauley to continue as principal financial and accounting officer until the filing of the Form 10-Q for the quarter ended March 31, 2026.
• Mr. Staab to be responsible for accounting and finance functions and serve as principal financial and accounting officer after the Form 10-Q filing.
• Advancement of TNX-103 (oral levosimendan) for the treatment of PH-HFpEF.

Key Dates

Recommendation

The filing announces a key executive appointment, which is a positive step for operational stability and financial oversight. However, the company remains in the development stage with significant clinical and regulatory risks ahead. The recommendation is 'hold' as the core value proposition and future success depend on the clinical trial outcomes and regulatory approvals of its lead drug candidate, rather than this executive change alone.

Keywords

Chief Financial Officer, CFO Appointment, Tenax Therapeutics, Thomas R. Staab, II, Healthcare Finance, Biotech, Pharmaceutical Development, PH-HFpEF